Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued
ANDA Sponsor And AstraZeneca Disagreed On Chances Of Settlement
Executive Summary
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.
You may also be interested in...
Zydus Knocked Back On Farxiga In US As Brand Continues To Grow
Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.
HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
Five Big Legal Stories From 2022
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.